TIMP2 Mouse Monoclonal Antibody
- Known as:
- TIMP2 Mouse Monoclonal Antibody
- Catalog number:
- ENZ-007077-M01J
- Product Quantity:
- 0.1mg
- Category:
- -
- Supplier:
- Zyagen
- Gene target:
- TIMP2 Mouse Monoclonal Antibody
Related genes to: TIMP2 Mouse Monoclonal Antibody
- Gene:
- TIMP2 NIH gene
- Name:
- TIMP metallopeptidase inhibitor 2
- Previous symbol:
- -
- Synonyms:
- CSC-21K
- Chromosome:
- 17q25.3
- Locus Type:
- gene with protein product
- Date approved:
- 1992-06-18
- Date modifiied:
- 2016-10-05
Related products to: TIMP2 Mouse Monoclonal Antibody
Related articles to: TIMP2 Mouse Monoclonal Antibody
- To investigate the effects of propranolol on the malignant biological behaviours of renal cancer cells and explore the potential involvement of the IL-6/PI3K/AKT signalling axis. - Source: PubMed
Publication date: 2026/09/11
Lu DongmingXie XuepingLiu YanmeiZhang TianyongFan HaimingLiao ShangfanWu Yongyang - To study post injury metabolite activity and glycocalyx shedding in older adults (OAs) compared to younger adults (YAs). Changes in the metabolome and the glycocalyx after injury are increasingly understood in YAs, but not in OAs. - Source: PubMed
Publication date: 2026/09/24
Anand TanyaRajakaruna SumuduJenkins Phillip DHilser AlexBrugere EstellePerry LauraParsawar KrishnaMagnotti Lou - Chronic kidney disease (CKD) requires assessment of both glomerular filtration and kidney damage, particularly albuminuria, for diagnosis, risk stratification, and longitudinal care. Point-of-care testing (POCT) can shorten turnaround time and improve access when conventional laboratory testing is unavailable or would delay a clinical pathway. This narrative review summarizes established and emerging POCT approaches for kidney assessment in CKD, with emphasis on creatinine/eGFR and urine albumin-to-creatinine ratio (UACR), and distinguishes analytical validity from workflow utility and patient-level clinical utility. Evidence is strongest for rapid creatinine measurement in selected workflows, especially pre-imaging assessment and decentralized screening, while quantitative/semiquantitative UACR POCT can support CKD detection when abnormal results are appropriately confirmed. Cystatin C microfluidic systems remain investigational, and kidney injury/stress or molecular biomarkers such as NGAL, KIM-1, L-FABP, [TIMP-2]ยท[IGFBP7], extracellular vesicles, and microRNAs should be regarded primarily as a research horizon rather than direct measures of GFR. Important implementation requirements include assay-specific validation, calibration traceability, quality assurance, recognition of biological and analytical interference, and confirmation of results near major clinical decision thresholds. Evidence that POCT improves long-term CKD outcomes, safety, adherence, or cost-effectiveness remains limited. Future studies should prioritize prospective clinical utility, implementation, cost-effectiveness, home-use validation, and patient-centered outcomes. - Source: PubMed
Publication date: 2026/08/27
Phongphithakchai AtthaphongWongna KraiyasakNetphakdee RatanaKlangbud Wiyada KwanhianThanasai JongkonneeKawakami FumitakaChatatikun Moragot - Synovial fluid biomarkers reflect the intra-articular response to an anterior cruciate ligament (ACL) rupture and may provide insight into biological processes associated with posttraumatic joint degeneration. While increasing age has been associated with inferior clinical outcomes after ACL reconstruction, age-dependent differences in biomarker expression and their relationship to longer term outcomes remain unclear. - Source: PubMed
Publication date: 2026/09/24
Ehlers MalloryKurtz Jessica LMontgomery Samuel RKaplan Daniel JStrauss Eric J - This study explores the therapeutic efficacy and mechanisms of panaxadiol (PD), a ginseng-derived sapogenin, in a mouse model of vascular cognitive impairmentinduced by chronic cerebral hypoperfusion (CCH). - Source: PubMed
Publication date: 2026/09/22
Bai XingyuMa YongxinWang ShuangQin HeJia HongboZhang MengChen SiyuXu Yaoming